Mannkind Soars 38.13% on Strategic Acquisition of scPharmaceuticals

Mannkind's stock surged by 38.13% in pre-market trading on September 2, 2025, driven by significant developments in the company's strategic acquisitions and market outlook.

Mannkind Corporation has entered into a definitive agreement to acquire scPharmaceuticals Inc. for approximately $290 million. This acquisition is expected to accelerate Mannkind's revenue growth and expand its cardiometabolic business. The deal has been met with positive reactions from analysts, with H.C. Wainwright reiterating a Buy rating on Mannkind and setting a price target of $9, citing the acquisition as a strategic move that aligns with the company's growth objectives.

Leerink Partners has also reiterated a Buy rating on Mannkind, maintaining a price target of $7. The consensus rating for Mannkind remains positive, with a score of 3.29 based on five buy ratings and no hold or sell ratings. This strong analyst support reflects the market's confidence in Mannkind's strategic direction and growth potential.

Mannkind's acquisition of scPharmaceuticals is seen as a significant step in expanding its product portfolio and enhancing its market position. The deal includes a cash payment of $5.35 per share plus a contingent value right, representing a 31% premium to the previous trading price. This acquisition is expected to drive Mannkind's growth in the cardiometabolic space, leveraging scPharmaceuticals' innovative technologies and products.